Five days of ceftriaxone to treat culture negative neutrocytic ascites in cirrhotic patients.
The goal of this study is to establish whether 5 days of ceftriaxone treatment was sufficient to cure culture-negative neutrocytic ascites in cirrhotic patients. We studied 50 cirrhotic patients with culture-negative neutrocytic ascites. All were treated with ceftriaxone, 1.0 g IV, twice a day for 5 days. A control paracentesis was performed 48 hours after starting the therapy to assess response to the treatment. A total of 17 demographic, clinical, and laboratory variables were recorded in all cases on the day of diagnosis of CNNA. The mean age of the patients was 57.7 +/- 13.2 years. Thirty-two patients were males and 18 females. The etiology of cirrhosis was hepatitis C virus in 20 patients (40%), hepatitis B virus in 16 patients (32%), cryptogenic in 13 patients (26%), and alcohol abuse in 1 patient (2%). Eighty percent of the patients were in Child-Pugh Class C. Resolution rate of culture-negative neutrocytic ascites on day 5 of treatment was 78%. Hospital mortality in cirrhotic patients with culture negative neutrocytic ascites was 4%. Statistical analysis showed that none of the 13 selected variables as covariates significantly related with the resolution of culture-negative neutrocytic ascites. Five days of ceftriaxone treatment is an adequate therapy for culture-negative neutrocytic ascites.
Baskol
Mevlut
M
Erciyes University School of Medicine, Kayseri, Turkey. mbaskol@kayseri.edu.tr
Gursoy
Sebnem
S
Baskol
Gulden
G
Ozbakir
Omer
O
Guven
Kadri
K
Yucesoy
Mehmet
M
D000328:Adult; D000368:Aged; D001201:Ascites / Q000188:drug therapy* / Q000382:microbiology; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D001431:Bacteriological Techniques; D002443:Ceftriaxone / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D009504:Neutrophils; D010538:Peritonitis / Q000188:drug therapy* / Q000382:microbiology; D016896:Treatment Outcome
D002443:Ceftriaxone